ArticleJournal of the American Heart Association2026
Multiomics Insights Into the Role of Spondin-1 in the Pathogenesis and Prognosis of Atrial Fibrillation.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtrial fibrillation (AF) is characterized by progressive structural remodeling, yet molecular drivers remain incompletely understood. This study aimed to identify novel protein targets for AF using an integrative multiomics approach.
methodsWe performed a multilayered genetic screen combining Mendelian randomization and colocalization analyses of plasma protein (protein quantitative trait loci) and atrial expression quantitative trait loci with AF genome-wide association studies. SPON1 (spondin-1) was identified as a priority candidate and further characterized using single-nucleus RNA sequencing, spatial transcriptomics, and experimental validation. Clinical relevance was evaluated in the UK Biobank cohort by assessing associations with incident AF, cardiac magnetic resonance phenotypes, and long-term prognosis.
resultsThe genetic screen identified SPON1 as a potential target for AF, supported by colocalization evidence across the plasma proteome (posterior probability of hypothesis 4=0.87) and atrial transcriptome (posterior probability of hypothesis 4=0.86). Single-cell and spatial transcriptomics revealed that SPON1 expression was specific to fibroblasts and enriched in extracellular matrix pathways. In the UK Biobank cohort (N=39 372), elevated plasma SPON1 levels were independently associated with an increased risk of incident AF (hazard ratio [HR], 1.17;
conclusionsIn conclusion, this integrative study identifies SPON1 as a candidate with potential causal and prognostic relevance for AF. These findings suggest that targeting this protein may offer a strategy for modifying the structural substrate of AF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.